Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration

References

• Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. 2007. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 85:525–535.
   PubMed Web of Science ®Google Scholar
• Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amosse C, . 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367:553–561.
   PubMed Web of Science ®Google Scholar
• Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. 2006. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 59: 1087–1096.
   PubMed Web of Science ®Google Scholar
• Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E. 2005. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 29:908–916.
   PubMed Web of Science ®Google Scholar
• Begliuomini S, Lenzi E, Ninni F, Casarosa E, Merlini S, Pluchino N, . 2008. Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol 197:429–435.
   Google Scholar
• Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E. 2006. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 17: 703–713.
   PubMed Web of Science ®Google Scholar
• Bourin M, Mocaer E, Porsolt R. 2004. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 29: 126–133.
   PubMed Web of Science ®Google Scholar
• Bova R, Micheli MR, Qualadrucci P, Zucconi GG. 1998. BDNF and trkB mRNAs oscillate in rat brain during the light-dark cycle. Brain Res Mol Brain Res 57: 321–324.
   PubMedGoogle Scholar
• Bramham CR, Messaoudi E. 2005. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76: 99–125.
   PubMed Web of Science ®Google Scholar
• Cajochen C, Krauchi K, Wirz-Justice A. 2003. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15: 432–437.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Molteni R, Racagni G, Riva MA. 2009. Neuronal plasticity: A link between stress and mood disorders. Psychoneuroendocrinology: Castren E. 2005. Is mood chemistry? Nat Rev Neurosci 6: 241–246.
   Google Scholar
• Cirelli C, Tononi G. 2000. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci 20: 9187–9194.
   PubMed Web of Science ®Google Scholar
• Cohen S, Greenberg ME. 2008. Communication between the synapse and the nucleus in neuronal development, plasticity, and disease. Annu Rev Cell Dev Biol 24: 183–209.
   PubMedGoogle Scholar
• Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, . 2008. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berlin) 199: 549–568.
   PubMed Web of Science ®Google Scholar
• Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U. 1999. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91: 587–597.
   PubMed Web of Science ®Google Scholar
• Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E. 2006. Central serotonin2C receptor: from physiology to pathology. Curr Top Med Chem 6: 1909–1925.
   Google Scholar
• Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116–1127.
   PubMed Web of Science ®Google Scholar
• Giorgetti M, Tecott LH. 2004. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 488: 1–9.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. 2000. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 61(Suppl 6): 4–6.
   Google Scholar
• Holmes MC, French KL, Seckl JR. 1997. Dysregulation of diurnal rhythms of serotonin 5-HT2C and corticosteroid receptor gene expression in the hippocampus with food restriction and glucocorticoids. J Neurosci 17: 4056–4065.
   Web of Science ®Google Scholar
• Imbesi M, Uz T, Dzitoyeva S, Manev H. 2008. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells. Neurosci Lett 439: 34–36.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16: 93–100.
   PubMed Web of Science ®Google Scholar
• Liang FQ, Walline R, Earnest DJ. 1998. Circadian rhythm of brain-derived neurotrophic factor in the rat suprachiasmatic nucleus. Neurosci Lett 242: 89–92.
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D’Haenen H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17: 239–247.
   PubMed Web of Science ®Google Scholar
• Martinowich K, Manji H, Lu B. 2007. New insights into BDNF function in depression and anxiety. Nat Neurosci 10: 1089–1093.
   PubMed Web of Science ®Google Scholar
• Millan MJ. 2005. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441–460.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, . 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of fronto-cortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306: 954–964.
   PubMed Web of Science ®Google Scholar
• Molteni R, Calabrese F, Cattaneo A, Mancini M, Gennarelli M, Racagni G, . 2009. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology 34: 1523–1532.
   PubMed Web of Science ®Google Scholar
• Molteni R, Lipska BK, Weinberger DR, Racagni G, Riva MA. 2001. Developmental and stress-related changes of neurotrophic factor gene expression in an animal model of schizophrenia. Mol Psychiatry. 6: 285–292.
   Google Scholar
• Moyer RW, Kennaway DJ. 1999. Immunohistochemical localization of serotonin receptors in the rat suprachiasmatic nucleus. Neurosci Lett 271: 147–150.
   PubMedGoogle Scholar
• Olie JP, Kasper S. 2007. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10: 661–673.
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, . 2008. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 85: 335–353.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28: 694–703.
   PubMed Web of Science ®Google Scholar
• Paxinos G, Watson C. 1996. The rat brain in stereotaxis coordinates. New York: Academic Press.
   Google Scholar
• Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, . 2009. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34: 2390–2403.
   PubMed Web of Science ®Google Scholar